Tirzepatide linked to heart structure improvement and better heart relaxation in obesity-related heart failure with preserved pumping

Real-world echocardiographic evidence of cardiac reverse remodeling in obesity-related heart failure with preserved ejection fraction (HFpEF) remains limited.

• Obesity-related HFpEF is marked by changes in heart structure and function, including concentric remodeling and diastolic dysfunction.
• Tirzepatide is associated with significant weight loss in patients.
• The connection between tirzepatide-induced weight loss and cardiac reverse remodeling in HFpEF is not well established in prospective studies.

Simplified